CompsDesk

Arbutus Biopharma Corp (ABUS) — benchmarks from SEC filings

Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%

$14MRevenue FY2025
128.2%Revenue growth
-271.0%Operating margin
-237.9%Net margin
-281.5%FCF margin
Fiscal yearRevenueOp marginNet margin
FY2025$14M-271.0%-237.9%
FY2024$6M-1236.7%-1133.0%
FY2023$18M-430.5%-401.6%
FY2022$39M-167.8%-178.0%
FY2021$11M-669.1%-693.9%

How does ABUS compare against its actual peer set?

The full CompsDesk Peer Benchmark Pack: 13 metrics × 5 years × your chosen peers, percentile placement, provenance for every number, board-ready PDF. One-off $249 — see a free sample pack first.

Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.